(Q79294759)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14618238%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

title

The vasopeptidase inhibitor AVE7688 ameliorates Type 2 diabetic nephropathy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14618238%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14618238%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

author name string

S Schäfer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14618238%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

W Linz

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14618238%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

H Vollert

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14618238%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

G Biemer-Daub

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14618238%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

H Rütten

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14618238%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

A E Busch

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14618238%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

publication date

14 November 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14618238%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14618238%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

volume

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14618238%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14618238%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

page(s)

98-103

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14618238%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00125-003-1264-8

21 December 2019

exact match

0 references

cites work

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

1 reference

12 December 2020

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

1 reference

12 December 2020

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

12 December 2020

Vasopeptidase inhibitors: a new class of dual zinc metallopeptidase inhibitors for cardiorenal therapeutics

1 reference

12 December 2020

The angiotensin II receptor antagonist losartan reduces blood pressure but not renal injury in obese Zucker rats

1 reference

12 December 2020

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

1 reference

12 December 2020

Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy

1 reference

12 December 2020

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

1 reference

12 December 2020

Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats

1 reference

12 December 2020

Vasopeptidase inhibition affords greater renoprotection than angiotensin-converting enzyme inhibition alone.

1 reference

12 December 2020

Diabetic nephropathy: can renoprotection be extrapolated to cardiovascular protection?

1 reference

12 December 2020

Renal disease and hypertension in non-insulin-dependent diabetes mellitus.

1 reference

12 December 2020

Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I

1 reference

12 December 2020

Dual ACE and NEP inhibitor MDL-100,240 prevents and regresses severe angiotensin II-dependent hypertension partially through bradykinin type 2 receptor

1 reference

12 December 2020

Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy

1 reference

12 December 2020

The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient?

1 reference

12 December 2020

Effects of omapatrilat on blood pressure and renal injury in L-NAME and L-NAME plus DOCA-treated rats

1 reference

12 December 2020

Pathogenesis, prevention, and treatment of diabetic nephropathy

1 reference

12 December 2020

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

12 December 2020

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial

1 reference

12 December 2020

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

12 December 2020

Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men

1 reference

12 December 2020

The intrarenal renin-angiotensin system and diabetic nephropathy

1 reference

12 December 2020

Podocyte injury promotes progressive nephropathy in zucker diabetic fatty rats

1 reference

12 December 2020

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

12 December 2020